MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
477.92
+19.11
+4.17%
After Hours: 477.17 -0.75 -0.16% 19:43 02/06 EST
OPEN
459.69
PREV CLOSE
458.81
HIGH
478.28
LOW
459.00
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
519.68
52 WEEK LOW
362.50
MARKET CAP
121.26B
P/E (TTM)
33.58
1D
5D
1M
3M
1Y
5Y
1D
2 Top Healthcare Stocks to Buy in February
The Motley Fool · 9h ago
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Autoimmune Pipeline Expansion With WuXi Biologics
Simply Wall St · 1d ago
Does WuXi Trispecific T-cell Engager Deal Reshape the Bull Case for Vertex Pharmaceuticals (VRTX)?
Simply Wall St · 2d ago
Vertex Pharmaceuticals Files Initial Statement of Beneficial Ownership for Mark E. Bunnage, EVP and Chief Scientific Officer
Reuters · 4d ago
Vertex Pharmaceuticals, WuXi Biologics enter license and research service pact
TipRanks · 4d ago
WuXi Biologics Jumps On Pact With Vertex Pharma For T-Cell Engager In Autoimmune Disease
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Brookdale Senior Living (BKD)
TipRanks · 4d ago
WuXi Biologics schließt Lizenz- und Forschungsdienstleistungsvertrag mit Vertex Pharmaceuticals für T-Zell-Engager ab
Reuters · 4d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Webull offers Vertex Pharmaceuticals Inc stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.